FrancophonIA/ELRC3.0 huggingface dataset:
English: Zerbaxa is available in packs containing 20 mL Type I clear glass vial with stopper (bromobutyl rubber) and flip-off seal.
Croatian: Zerbaxa je dostupna u pakiranjima koja sadrže bočicu volumena 20 ml od prozirnog stakla tipa
English: These enzymes make bacteria resistant to ceftolozane by breaking down the antibiotic before it can act. By blocking their action, tazobactam makes ceftolozane more effective at killing bacteria.
Croatian: Ti enzimi razgrade antibiotik prije nego što uspije djelovati i zbog njih su bakterije rezistentne na ceftolozan.
English: Blood and the lymphatic system disorders
Croatian: Poremećaji krvi i limfnog sustava trombocitoza anemija
English: Table 1: Intravenous dose of Zerbaxa by type of infection in patients with creatinine clearance > 50 mL/min
Croatian: Tablica 1: Intravenska doza lijeka Zerbaxa prema vrsti infekcije u bolesnika s klirensom kreatinina >50 ml/min
English: Ceftolozane/tazobactam is also contraindicated in patients with severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta-lactam antibacterial agent (e.g., penicillins or carbapenems) (see section 4.3).
Croatian: Ceftolozan/tazobaktam je kontraindiciran i u bolesnika s teškom preosjetljivošću (npr. anafilaktička reakcija, jaka kožna reakcija) na bilo koju drugu vrstu beta-laktamskih antibiotika (npr. peniciline ili karbapeneme) (vidjeti dio 4.3).
English: Ceftolozane/tazobactam contains 230 mg sodium per vial, equivalent to 11.5% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Croatian: Ceftolozan/tazobaktam sadrži 230 mg natrija po bočici, što odgovara 11,5% maksimalnog dnevnog unosa od 2 g natrija prema preporukama SZO za odraslu osobu.
English: Aseptic technique must be followed in preparing the infusion solution.
Croatian: Kod pripreme infuzijske otopine obavezno je pridržavati se aseptičke tehnike.
English: The mean (coefficient of variation CV%) steady-state volume of distribution of ceftolozane/tazobactam in healthy adult males (n=51) following a single 1 g / 0.5 g IV dose was 13.5 L (21%) and 18.2 L (25%) for ceftolozane and tazobactam, respectively, similar to extracellular fluid volume.
Croatian: Srednja vrijednost (koeficijent varijacije, CV%) volumena distribucije ceftolozana/tazobaktama u stanju dinamičke ravnoteže u zdravih odraslih muškaraca (n=51) nakon jednokratne intravenske doze od 1 g/0,5 g iznosila je 13,5 l (21%) za ceftolozan i 18,2 l (25%) za tazobaktam, slično volumenu izvanstanične tekućine.
English: When the powder is reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, the vial contains 11.5 mmol (265 mg) of sodium.
Croatian: Kad se prašak rekonstituira s 10 ml otopine natrijevog klorida za injekciju od 9 mg/ml (0,9%), bočica sadrži 11,5 mmol (265 mg) natrija.
English: 1, anxiety Nervous system disorders Headache
Croatian: Poremećaji živčanog sustava glavobolja
English: The beta-lactam ring of tazobactam is hydrolyzed to form the pharmacologically inactive, tazobactam metabolite M1.
Croatian: Hidrolizom beta-laktamskog prstena tazobaktama nastaje farmakološki nedjelatan metabolit tazobaktama M1.
English: Ceftolozane, tazobactam and the tazobactam metabolite M1 are eliminated by the kidneys.
Croatian: Ceftolozan, tazobaktam i metabolit tazobaktama M1 eliminiraju se putem bubrega.
English: Zerbaxa solution for infusion is clear and colourless to slightly yellow.
Croatian: Otopina za infuziju lijeka Zerbaxa bistra je i bezbojna do žućkasta.
English: **Based on 2 g ceftolozane / 1 g tazobactam intravenously every 8 hours.
Croatian: **Na temelju 2 g ceftolozana/1 g tazobaktama, intravenski svakih 8 sati.
English: In clinical studies, there was no evidence of haemolysis in patients who developed a positive DAGT on treatment.
Croatian: U kliničkim ispitivanjima nije bilo znakova hemolize u bolesnika koji su tijekom liječenja razvili pozitivan rezultat na DAGT-u.
English: Complicated urinary tract infections, including pyelonephritis
Croatian: Komplicirane infekcije mokraćnog sustava, uključujući pijelonefritis
English: Ceftolozane/tazobactam is contraindicated in patients with a history of hypersensitivity to ceftolozane, tazobactam, or cephalosporins (see section 4.3).
Croatian: Ceftolozan/tazobaktam je kontraindiciran u bolesnika koji u anamnezi imaju preosjetljivost na ceftolozan, tazobaktam ili cefalosporine (vidjeti dio 4.3).
English: Following a single 1-hour intravenous infusion of 2 g / 1 g ceftolozane/tazobactam to critically ill patients with CrCL greater than or equal to 180 mL/min (N=10), mean terminal half-life values of ceftolozane and tazobactam were 2.6 hours and 1.5 hours, respectively.
Croatian: Nakon jedne jednosatne intravenske infuzije ceftolozana/tazobaktama u dozi od 2 g/1 g kritično bolesnim bolesnicima s CrCL-om od 180 ml/min (N=10) ili većim, srednja vrijednost terminalnog poluvijeka ceftolozana iznosila je 2,6 sati, a tazobaktama 1,5 sat.
English: Clostridioides difficile-associated diarrhoea
Croatian: Dijareja povezana s Clostridioides difficile
English: As ceftolozane/tazobactam does not undergo hepatic metabolism, the systemic clearance of ceftolozane/tazobactam is not expected to be affected by hepatic impairment.
Croatian: Budući da se ceftolozan/tazobaktam ne metabolizira u jetri, ne očekuje se da će oštećenje funkcije jetre utjecati na sistemski klirens ceftolozana/tazobaktama.
English: Ceftolozane/tazobactam and the tazobactam metabolite M1 are eliminated by the kidneys.
Croatian: Ceftolozan/tazobaktam i metabolit tazobaktama M1 eliminiraju se bubrezima.
English: The powder for concentrate for solution for infusion for each vial is reconstituted with 10 mL of water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection per vial; following reconstitution the vial should be shaken gently to dissolve the powder.
Croatian: Prašak za koncentrat za otopinu za infuziju iz svake bočice rekonstituira se s 10 ml vode za injekcije ili otopine natrijevog klorida za injekciju od 9 mg/ml (0,9%) po bočici; nakon rekonstitucije bočicu treba nježno protresti kako bi se prašak otopio.
English: In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in exposure were observed with regard to age.
Croatian: U analizi populacijske farmakokinetike ceftolozana/tazobaktama nisu opažene klinički značajne razlike u izloženosti s obzirom na dob.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE OF ADMINISTRATION
Croatian: NAZIV LIJEKA I PUT(EVI) PRIMJENE LIJEKA
English: Applies across all indications: complicated intra-abdominal infections, acute pyelonephritis, complicated urinary tract infections, and hospital-acquired pneumonia, including ventilator-associated pneumonia.
Croatian: Primjenjivo na sve indikacije: komplicirane intraabdominalne infekcije, akutni pijelonefritis, komplicirane infekcije mokraćnog sustava i bolničku pneumoniju, uključujući pneumoniju povezanu s mehaničkom ventilacijom.
English: Complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis**
Croatian: Komplicirane intraabdominalne infekcije, komplicirane infekcije mokraćnog sustava i akutni pijelonefritis**
English: Following 1 hour intravenous infusions of 2 g / 1 g ceftolozane/tazobactam or adjusted based on renal function every 8 hours in ventilated patients with confirmed or suspected pneumonia (N=22), ceftolozane and tazobactam concentrations in pulmonary epithelial lining fluid were greater than 8 mcg/mL and 1 mcg/mL, respectively, over 100% of the dosing interval.
Croatian: Nakon 1 sata intravenske infuzije ceftolozana/tazobaktama u dozi od 2 g/1 g ili dozi prilagođenoj prema funkciji bubrega primijenjenoj svakih 8 sati bolesnicima na mehaničkoj ventilaciji s dokazanom pneumonijom ili sumnjom na pneumoniju (N=22), koncentracije ceftolozana i tazobaktama u tekućini koja oblaže plućni epitel bile su veće od 8 μg/ml za ceftolozan, odnosno 1 μg/ml za tazobaktam tijekom 100% intervala doziranja.
English: Hospital-acquired pneumonia, including ventilator-associated pneumonia
Croatian: Bolnička pneumonija, uključujući pneumoniju povezanu s mehaničkom ventilacijom
English: 1, abdominal distension dyspepsia
Croatian: 1, distenzija abdomena
English: What Zerbaxa looks like and contents of the pack Zerbaxa is a white to slightly yellow powder for concentrate for solution for infusion (powder for concentrate) supplied in a vial.
Croatian: Zerbaxa je bijeli do žućkasti prašak za koncentrat za otopinu za infuziju (prašak za koncentrat) dostupan u bočici.
English: The development of a positive direct antiglobulin test (DAGT) may occur during treatment with ceftolozane/tazobactam (see section 4.8).
Croatian: Tijekom liječenja ceftolozanom/tazobaktamom može doći do razvoja pozitivnog rezultata direktnog antiglobulinskog testa (DAGT) (vidjeti dio 4.8).
English: In vitro data indicate that ceftolozane did not inhibit P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, MRP, BSEP, OAT1, OAT3, MATE1, or MATE2-K in vitro at therapeutic plasma concentrations.
Croatian: In vitro podaci pokazuju da ceftolozan nije inhibirao P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, MRP, BSEP, OAT1, OAT3, MATE1 ili MATE2-K in vitro pri terapijskim koncentracijama u plazmi.
English: Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion
Croatian: Zerbaxa 1 g/0,5 g prašak za koncentrat za otopinu za infuziju
English: Sodium chloride, arginine, citric acid, anhydrous
Croatian: Natrijev klorid, arginin, bezvodna citratna kiselina
English: The elimination half-life (t½) of ceftolozane is independent of dose.
Croatian: Poluvijek eliminacije (t½) ceftolozana ne ovisi o primijenjenoj dozi.
English: In vitro data indicate that neither tazobactam nor the tazobactam metabolite M1 inhibit P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, or BSEP transporters at therapeutic plasma concentrations.
Croatian: In vitro podaci pokazuju da ni tazobaktam niti metabolit tazobaktama M1 ne inhibiraju P-gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2 ili BSEP transportere pri terapijskim koncentracijama u plazmi.
English: Specific for the complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections indications treated with Zerbaxa (1 g / 0.5 g intravenously every 8 hours) for up to 14 days.
Croatian: Specifično za indikacije kompliciranih intraabdominalnih infekcija, akutnog pijelonefritisa i kompliciranih infekcija mokraćnog sustava liječenih lijekom Zerbaxa (1 g/0,5 g intravenski svakih 8 sati) do 14 dana.
English: Hospital-acquired pneumonia, including ventilator-associated pneumonia**
Croatian: Bolnička pneumonija, uključujući pneumoniju povezanu s mehaničkom ventilacijom**
English: 500 mg ceftolozane / 250 mg tazobactam intravenously every 8 hours
Croatian: 500 mg ceftolozana/250 mg tazobaktama intravenski svakih 8 sati
English: The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 265 mg sodium in each vial.
Croatian: Bočica rekonstituirana s 10 ml 0,9%-tne otopine natrijevog klorida (fiziološka otopina) za injekciju sadrži 265 mg natrija u svakoj bočici.
English: 250 mg ceftolozane / 125 mg tazobactam intravenously every 8 hours
Croatian: 250 mg ceftolozana/125 mg tazobaktama intravenski svakih 8 sati
English: The ceftolozane dose normalized geometric mean AUC increased up to 1.26-fold, 2.5-fold, and 5-fold in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects with normal renal function.
Croatian: Geometrijska srednja vrijednost AUC-a ceftolozana normalizirana na dozu povećala se do 1,26 puta u ispitanika s blagim oštećenjem funkcije bubrega, do 2,5 puta u ispitanika s umjerenim oštećenjem funkcije bubrega i do 5 puta u ispitanika s teškim oštećenjem funkcije bubrega u usporedbi sa zdravim ispitanicima s normalnom funkcijom bubrega.
English: Hospital-acquired pneumonia, including ventilator-associated pneumonia** *Based on 1 g ceftolozane / 0.5 g tazobactam intravenously every 8 hours.
Croatian: H. influenzae bolnička pneumonija, uključujući pneumoniju povezanu s mehaničkom ventilacijom** *Na temelju 1 g ceftolozana/0,5 g tazobaktama, intravenski svakih 8 sati.
English: Zerbaxa was evaluated in a Phase 3 comparator-controlled clinical trial of hospital-acquired pneumonia, including ventilator-associated pneumonia, which included a total of 361 patients, treated with Zerbaxa (2 g / 1 g intravenously every 8 hours, adjusted to match renal function where appropriate) for up to 14 days.
Croatian: Zerbaxa je ocijenjena u komparatorom kontroliranom kliničkom ispitivanju faze 3 kod bolničke pneumonije, uključujući i pneumoniju povezanu s mehaničkom ventilacijom, koje je uključilo ukupno 361 bolesnika liječenog lijekom Zerbaxa (2 g/1 g intravenski, svakih 8 sati, prilagođeno da odgovara bubrežnoj funkciji kad je to bilo potrebno) do 14 dana.
English: No significant medicinal product interactions are anticipated between ceftolozane/tazobactam and substrates, inhibitors, and inducers of cytochrome P450 enzymes (CYPs) based on in vitro and in vivo studies.
Croatian: Na temelju ispitivanja in vitro i in vivo, ne očekuju se značajne interakcije lijekova između ceftolozana/tazobaktama i supstrata, inhibitora i induktora enzima citokroma P450 (CYP).
English: Dizziness may occur following administration of Zerbaxa (see section 4.8).
Croatian: Nakon primjene lijeka Zerbaxa može nastupiti omaglica (vidjeti dio 4.8).
English: How to store Zerbaxa
Croatian: Kako čuvati lijek Zerbaxa
English: No dose adjustment is recommended for ceftolozane/tazobactam in subjects with hepatic impairment (see section 4.2).
Croatian: Ne preporučuje se prilagodba doze ceftolozana/tazobaktama u ispitanika s oštećenjem funkcije jetre (vidjeti dio 4.2).
English: Specific for the hospital-acquired pneumonia, including ventilator-associated pneumonia indication treated with Zerbaxa (2 g / 1 g intravenously every 8 hours) for up to 14 days.
Croatian: Specifično za indikaciju bolničke pneumonije, uključujući pneumoniju povezanu s mehaničkom ventilacijom liječenu lijekom Zerbaxa (2 g/1 g intravenski svakih 8 sati) do 14 dana.
English: The following adverse reactions have been identified during clinical trials with Zerbaxa.
Croatian: Tijekom kliničkih ispitivanja s lijekom Zerbaxa ustanovljene su sljedeće nuspojave.
English: Zerbaxa was evaluated in Phase 3 comparator-controlled clinical trials of complicated intra-abdominal infections and complicated urinary tract infections (including pyelonephritis), which included a total of 1,015 patients, treated with Zerbaxa (1 g / 0.5 g intravenously every 8 hours, adjusted to match renal function where appropriate) for up to 14 days.
Croatian: Zerbaxa je ocijenjena u komparatorom kontroliranim kliničkim ispitivanjima faze 3 kod kompliciranih intraabdominalnih infekcija i kompliciranih infekcija mokraćnog sustava (uključujući pijelonefritis), koja su uključila ukupno 1015 bolesnika liječenih lijekom Zerbaxa (1 g/0,5 g intravenski svakih 8 sati, prilagođeno da odgovara bubrežnoj funkciji kad je to bilo potrebno) do 14 dana.
English: Headache, stomach ache, constipation, diarrhoea, nausea, vomiting, increase in liver enzymes (from blood tests), rash, fever (high temperature), decrease in blood pressure, decrease in potassium (from blood tests), increase in the number of certain types of blood cells known as platelets, dizziness, anxiety, difficulty sleeping, infusion site reactions
Croatian: Bolesnici koji se liječe zbog kompliciranih infekcija u trbuhu i infekcija bubrega i mokraćnog sustava Česte nuspojave (mogu se javiti u do 1 na 10 osoba): glavobolja, bol u trbuhu, zatvor, proljev, mučnina, povraćanje, povišeni jetreni enzimi (na krvnim pretragama), osip, vrućica (povišena tjelesna temperatura), sniženje krvnog tlaka, sniženje kalija (na krvnim pretragama), povećanje broja jedne vrste krvnih stanica koje se zovu krvne pločice, omaglica, tjeskoba, tegobe sa spavanjem, reakcije na mjestu primjene infuzije.
English: Gram-negative bacteria Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa
Croatian: Gram-negativne bakterije Enterobacter cloacae Escherichia coli Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis
English: Patients who were immunocompromised, patients with severe neutropenia, and patients with end stage renal disease on haemodialysis were excluded from clinical trials.
Croatian: U klinička ispitivanja nisu bili uključeni imunokompromitirani bolesnici, bolesnici s teškom neutropenijom ni bolesnici sa završnim stadijem bolesti bubrega na hemodijalizi.
English: Patients with kidney problems
Croatian: Bolesnici s bubrežnim tegobama
English: The reconstituted vial with 10 mL of 0.9% sodium chloride (normal saline) for injection contains 265 mg sodium per vial, equivalent to 13.3% of the WHO recommended maximum daily intake of 2 g sodium for an adult.
Croatian: Sadržaj bočice rekonstituiran s 10 ml 0,9%-tne otopine natrijevog klorida (fiziološke otopine) za injekciju sadrži 265 mg natrija po bočici, što odgovara 13,3% maksimalnog dnevnog unosa od 2 g natrija prema preporukama SZO za odraslu osobu.
English: Zerbaxa 1 g / 0.5 g powder for concentrate ceftolozane / tazobactam
Croatian: Zerbaxa 1 g/0,5 g prašak za koncentrat ceftolozan/tazobaktam
English: A single loading dose of 500 mg ceftolozane / 250 mg tazobactam followed after 8 hours by a 100 mg ceftolozane / 50 mg tazobactam maintenance dose administered every 8 hours for the remainder of the treatment period (on haemodialysis days, the dose should be administered at the earliest possible time following completion of haemodialysis)
Croatian: Jedna udarna doza od 500 mg ceftolozana/250 mg tazobaktama, nakon koje se, 8 sati kasnije, primjenjuje doza održavanja od 100 mg ceftolozana/50 mg tazobaktama svakih 8 sati tijekom preostalog razdoblja liječenja (na dane hemodijalize, dozu treba primijeniti što je prije moguće nakon završetka hemodijalize)
English: Approximately 82% of all patients in the trial had APACHE II (Acute Physiology and Chronic Health Evaluation II) scores of < 10 and 2.3% had bacteraemia at baseline.
Croatian: Približno 82% svih bolesnika u ispitivanju imalo je rezultat <10 bodova po APACHE II (engl.
English: Atrial fibrillation 1, tachycardia angina pectoris
Croatian: 1, angina pektoris
English: The elimination half-life (t½) of ceftolozane or tazobactam is independent of dose.
Croatian: Poluvijek eliminacije (t½) ceftolozana ili tazobaktama ne ovisi o primijenjenoj dozi.
English: Zerbaxa 1 g / 0.5 g powder for concentrate for solution for infusion ceftolozane / tazobactam
Croatian: Zerbaxa 1 g/0,5 g prašak za koncentrat za otopinu za infuziju ceftolozan/tazobaktam
English: A single loading dose of 1.5 g ceftolozane / 0.75 g tazobactam followed after 8 hours by a 300 mg ceftolozane / 150 mg tazobactam maintenance dose administered every 8 hours for the remainder of the treatment period (on haemodialysis days, the dose should be administered at the earliest possible time following completion of haemodialysis)
Croatian: Jedna udarna doza od 1,5 g ceftolozana/0,75 g tazobaktama, nakon koje se, 8 sati kasnije, primjenjuje doza održavanja od 300 mg ceftolozana/150 mg tazobaktama svakih 8 sati tijekom preostalog razdoblja liječenja (na dane hemodijalize, dozu treba primijeniti što je prije moguće nakon završetka hemodijalize)
English: How to take Zerbaxa
Croatian: Kako primjenjivati lijek Zerbaxa
English: 1 g ceftolozane / 0.5 g tazobactam intravenously every 8 hours
Croatian: 1 g ceftolozana/0,5 g tazobaktama intravenski svakih 8 sati
English: In clinical studies, there was no evidence of haemolysis in patients who developed a positive direct Coombs test in any treatment group.
Croatian: Ni u jednoj terapijskoj skupini u kliničkim ispitivanjima nije bilo dokaza hemolize u bolesnika u kojih je direktni Coombsov test postao pozitivan.
English: The recommended dose in complicated intra-abdominal infections, complicated urinary tract infections, and acute pyelonephritis subjects with end stage renal disease on haemodialysis is a single loading dose of 500 mg / 250 mg ceftolozane/tazobactam followed by a 100 mg / 50 mg maintenance dose of ceftolozane/tazobactam administered every 8 hours for the remainder of the treatment period.
Croatian: U ispitanika sa završnim stadijem bolesti bubrega i kompliciranim intraabdominalnim infekcijama, kompliciranim infekcijama mokraćnog sustava i akutnim pijelonefritisom koji su na hemodijalizi, preporučena doza je jednokratna udarna doza od 500 mg/250 mg ceftolozana/tazobaktama nakon koje slijedi primjena doze održavanja od 100 mg/50 mg ceftolozana/tazobaktama svakih 8 sati tijekom preostalog razdoblja liječenja.
English: In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in AUC were observed for ceftolozane and tazobactam.
Croatian: U analizi populacijske farmakokinetike ceftolozana/tazobaktama nisu opažene klinički značajne razlike u AUC-u ceftolozana i tazobaktama.
English: Gram-negative bacteria Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis Pseudomonas aeruginosa Serratia marcescens
Croatian: Gram-negativne bakterije Enterobacter cloacae Escherichia coli Haemophilus influenzae Klebsiella oxytoca Klebsiella pneumoniae Proteus mirabilis
English: In vitro data indicate that the following species are not susceptible to ceftolozane/tazobactam: Staphylococcus aureus
Croatian: In vitro podaci ukazuju da sljedeće vrste nisu osjetljive na ceftolozan/tazobaktam:
English: Hepatic impairment No dose adjustment is necessary in patients with hepatic impairment (see section 5.2).
Croatian: U bolesnika s oštećenjem funkcije jetre nije potrebna prilagodba doze (vidjeti dio 5.2).
English: Infections caused by bacteria that are not sensitive to Zerbaxa or caused by a fungus can occur during or following treatment with Zerbaxa.
Croatian: Tijekom ili nakon liječenja lijekom Zerbaxa može doći do infekcija koje uzrokuju bakterije koje nisu osjetljive na lijek Zerbaxa ili infekcija koje uzrokuju gljivice.
English: End stage renal disease on haemodialysis
Croatian: Završni stadij bolesti bubrega uz hemodijalizu
English: Infections and infestations Clostridioides difficile colitis
Croatian: 1, infekcije uzrokovane bakterijom Clostridioides difficile
English: The recommended dose in hospital-acquired pneumonia, including ventilator-associated pneumonia subjects with end stage renal disease on haemodialysis is a single loading dose of 1.5 g / 0.75 g ceftolozane/tazobactam followed by a 300 mg / 150 mg maintenance dose of ceftolozane/tazobactam administered every 8 hours for the remainder of the treatment period.
Croatian: U ispitanika sa završnim stadijem bolesti bubrega i bolničkom pneumonijom, uključujući pneumoniju povezanu s mehaničkom ventilacijom, koji su na hemodijalizi, preporučena doza je jednokratna udarna doza od 1,5 g/0,75 g ceftolozana/tazobaktama nakon koje slijedi primjena doze održavanja od 300 mg/150 mg svakih 8 sati tijekom preostalog razdoblja liječenja.
English: Pathogen
Croatian: Patogen
English: Candidiasis including oropharyngeal and vulvovaginal Clostridioides difficile colitis fungal urinary tract infection Clostridioides difficile infection
Croatian: Infekcije i infestacije kolitis uzrokovan bakterijom Clostridioides difficile kandidijaza uključujući orofaringealnu i vulvovaginalnu kandidijazu kolitis uzrokovan bakterijom Clostridioides difficile gljivične infekcije mokraćnog sustava
English: It is unknown whether ceftolozane and tazobactam are excreted in human milk.
Croatian: Nije poznato izlučuju li se ceftolozan i tazobaktam u majčino mlijeko.
English: Respiratory, thoracic, and mediastinal disorders
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja dispneja
English: Patients treated for an infection of the lungs called “pneumonia” Common side effects (may affect up to 1 in 10 people): Inflammation of the large intestine due to C. difficile bacteria, diarrhoea, vomiting, increase in liver enzymes (from blood tests)
Croatian: Upala debelog crijeva uzrokovana bakterijom C. difficile, proljev, povraćanje, povišeni jetreni enzimi (na krvnim pretragama)